SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending due to the contentious saga surrounding its potential acquisition of Warner Bros. Discovery assets, which is complicated by a rival all-cash bid from Paramount Skydance and notable political opposition. This ongoing acquisition drama and a recent analyst price target adjustment have sharply divided investors, with many viewing the current valuation as an oversold buying opportunity ahead of impending earnings, while others remain bearish on debt concerns and continued stock weakness.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending due to reports of a Department of Justice probe into Fed Chair Jerome Powell, which many perceive as political pressure to influence interest rates and undermine the Federal Reserve's independence. The community is sharply divided, with some fearing significant market instability and a loss of investor confidence, while others express support for the action against Powell, leading to widespread anticipation of heightened volatility and potential market declines.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions is seeing heightened market attention following a new manufacturing partnership designed to strengthen global production and boost margins. This, combined with a recent private placement, has sparked active community discussion around both short squeeze potential due to its low float and concerns regarding upcoming share dilution. Traders are closely watching how these contrasting factors will influence its volatile price action.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is experiencing significant volatility amid intensified competition, as Amazon Pharmacy now offers a popular weight loss pill, alongside a recent downgrade by Bank of America citing lofty 2026 estimates. This combination has ignited a fierce debate among investors, with many bears predicting further declines and questioning the company's competitive moat, while bulls highlight institutional holding, international expansion, and the potential for a short squeeze based on Hims' long-term vision in personalized healthcare.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is trending after impressive CES demonstrations showcased its advanced agentic and voice AI solutions, including new partnerships with TomTom for automotive navigation and Richtech Robotics. Enthusiastic bulls anticipate a major rally and short squeeze, citing the company's innovative technology and growing client base as key differentiators against broader market skepticism and perceived price suppression. The conversation centers on SoundHound's potential as a specialized leader in the rapidly expanding conversational AI market, offering unique privacy-focused enterprise solutions.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is trending amidst significant clinical milestones for its Alpha DaRT targeted alpha radiation therapy, including breakthrough data for pancreatic cancer and the filing of its first FDA PMA module. The community eagerly anticipates an upcoming PMDA approval in Japan and impending institutional investment from Cathie Wood, driving widespread discussion about the company's potential for a substantial re-rating and broader market recognition.

BlackRock Institutional Trust Company N.A. - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is a focal point as market participants weigh potential Federal Reserve rate cuts against persistent inflation concerns and recent strong economic data, including GDP and jobless claims. A key discussion revolves around political pressure for lower rates, impacting the outlook for long-term Treasury yields, while global events also contribute to evolving risk sentiment.

SSgA Active Trust - SPDR Dow Jones Industrial Average ETF

The SPDR Dow Jones Industrial Average ETF is trending as a criminal probe into Federal Reserve Chair Jerome Powell by the Department of Justice fuels intense community debate about the central bank's independence and future monetary policy. Investors are closely monitoring the market's reaction, anticipating heightened volatility and reevaluating broader economic stability in light of these significant political developments affecting key sectors like financials.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

Invesco QQQ Trust is trending amid significant market uncertainty following reports of a criminal investigation into Federal Reserve Chair Jerome Powell by the Department of Justice. The community is actively debating the implications of this unprecedented political pressure on Fed independence, with many bracing for increased volatility in technology and growth stocks. While some view it as a fleeting political maneuver, others express deep concern about its potential impact on monetary policy and market stability.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Hepion Pharmaceuticals Inc. drew heightened attention from retail traders on Monday after the company disclosed that the Nasdaq Hearings Panel had ordered its delisting, citing violations of continued listing requirements.&nbsp;Trading in the company's common stock is set to be suspended at the open on Tuesday, with shares expected to move to the OTC Markets under the same ticker, HEPA.Hepion Pharmaceuticals shares closed down 18.8% at $0.32 on Monday, sliding 45% to $0.17 in after-hours trading.Retail sentiment on Stocktwits turned 'bullish' on Monday amid a 5,100% surge in 24-hour message volume.One user highlighted optimism around Hepion's core asset, Rencofilstat, describing it as a potentially "revolutionary" drug class.&nbsp;Rencofilstat is a cyclophilin inhibitor aimed at treating chronic liver diseases like NASH and hepatocellular carcinoma (HCC).The user suggested that although trial results may not be released soon, the drug could eventually displace existing therapies once they have been fully monetized.&nbsp;They added that the move to OTC "could get interesting."<stembedurl>https://stocktwits.com/BADBOYROY/message/614371348</stembedurl>Another user hoped the stock would be tradable on Robinhood after moving to the OTC market, suggesting the transition could trigger a strong upward move.<stembedurl>https://stocktwits.com/stock_trafficking/message/614386549</stembedurl>The delisting followed Nasdaq's determination that Hepion had failed to maintain the minimum bid price of $1.00 and was in breach of Rule 5101, which allows delisting of companies identified as public shells.Hepion recently entered a license agreement with New Day Diagnostics LLC to distribute tests for celiac disease, respiratory multiplex (COVID-19, Influenza A/B, RSV), H. pylori, and hepatocellular carcinoma (HCC).&nbsp;These tests carry CE marks, making them eligible for sale in Europe.The company had previously paused and then wound down its ASCEND-NASH Phase 2b trial for Rencofilstat, after enrolling 151 patients out of a planned 336.&nbsp;Approximately 80 patients completed a full year of treatment.The stock has declined 98.7% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic picture shows a hand holidng a capsule on 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

Hepion Pharma Stock Draws Bullish Retail Bets Despite Nasdaq Delisting Notice: 'Could Get Interesting'

Despite a sharp decline in stock price, retail traders are optimistic about the company's potential, citing its core asset Rencofilstat and speculating on a rebound following the OTC transition.

Equity

Hepion Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of drug therapy for treatment of chronic liver diseases. It focuses on the development of its product candidate, Rencofilstat, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. The company was founded on May 15, 2013 and is headquartered in Morristown, NJ.

Hepion Pharmaceuticals Inc

Yes — Rates Move Meaningfully Lower

Short-Term Dip, No Lasting Impact

No — Mostly Political Noise

Other – Comment Below

President Trump says he’s directing $200 billion into mortgage bond purchases to bring down rates and improve housing affordability. With questions around execution, authority, and real market impact, do you think this move will actually lower mortgage rates in 2026?

Will Trump’s Mortgage Bond Plan Actually Lower Rates in 2026?

HEPA
Hepion Pharmaceuticals Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest HEPA News

HEPAHepion Pharmaceuticals Inc